Emalex is in a late-stage clinical study of a new class of drug for patients with Tourette syndrome who have limited treatment options.
Latest News
Did you know that approximately 1 out of every 160 children (ages 5-17) in the U.S. has TS?
For more than 50 years, the Tourette Association of America (TAA) has provided support for people living with TS and other tic disorders.
At Emalex Biosciences, we are working diligently to help people with TS find relief from tics that not only often cause pain and injury but also social stigma and emotional distress.
We kick-off our series that explores the life and world of people living with TS starting with TAA President and CEO Amanda Talty.
Emalex Biosciences’ Expanded Access Program for Investigational Tourette Syndrome Drug Receives FDA Authorization
Emalex Biosciences’ Lead Candidate Meets Primary and Secondary Endpoints in Phase 3 Tourette Syndrome Study
Emalex Biosciences Named “Neuroscience Therapeutics Company Of The Year” by BioTech Breakthrough
Emalex is in a late-stage clinical study of a new class of drug for patients with Tourette syndrome who have limited treatment options.
Latest News
Did you know that approximately 1 out of every 160 children (ages 5-17) in the U.S. has TS?
For more than 50 years, the Tourette Association of America (TAA) has provided support for people living with TS and other tic disorders.
At Emalex Biosciences, we are working diligently to help people with TS find relief from tics that not only often cause pain and injury but also social stigma and emotional distress.
We kick-off our series that explores the life and world of people living with TS starting with TAA President and CEO Amanda Talty.
Emalex Biosciences’ Expanded Access Program for Investigational Tourette Syndrome Drug Receives FDA Authorization
By emalexadmin |
Emalex is in a late-stage clinical study of a new class of drug for patients with Tourette syndrome who have limited treatment options.
Did you know that approximately 1 out of every 160 children (ages 5-17) in the U.S. has TS?
For more than 50 years, the Tourette Association of America (TAA) has provided support for people living with TS and other tic disorders.
At Emalex Biosciences, we are working diligently to help people with TS find relief from tics that not only often cause pain and injury but also social stigma and emotional distress.
We kick-off our series that explores the life and world of people living with TS starting with TAA President and CEO Amanda Talty.
Emalex Biosciences’ Expanded Access Program for Investigational Tourette Syndrome Drug Receives FDA Authorization
By emalexadmin |
Emalex Biosciences’ Lead Candidate Meets Primary and Secondary Endpoints in Phase 3 Tourette Syndrome Study
By emalexadmin |